what are the Recommendations for Selecting an Anticoagulant Regimen—
Balancing Risks and Benefits?
In patients with AF and end-stage CKD or on dialysis, the direct thrombin inhibitor dabigatran or the factor Xa inhibitors rivaroxaban or edoxaban are not recommended because of the lack of evidence from clinical trials that benefit exceeds risk.S4.1.1-8?S4.1.1-11,S4.1.1-36?S4.1.1-38 MODIFIED: New data have been included. Edoxaban received FDA approval and has been added to the recommendation. LOE was updated from C to C-EO. (Section 4.1. in the 2014 AF Guideline)